Is There an App for That?

Por Gainor, Justin F.
Publicado em 2012

Alectinib—a new chapter in the management of ALK-positive lung cancer

Por Gainor, Justin F.
Publicado no Transl Lung Cancer Res (2016)

Novel Targets in Non-Small Cell Lung Cancer: ROS1 and RET Fusions

Por Gainor, Justin F., Shaw, Alice T.
Publicado em 2013

Emerging Paradigms in the Development of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer

Por Gainor, Justin F., Shaw, Alice T.
Publicado em 2013

Ponatinib: Accelerated Disapproval

Por Gainor, Justin F., Chabner, Bruce A.
Publicado no Oncologist (2015)

Immune Checkpoint Inhibitors in Non‐Small Cell Lung Cancer

Por Herzberg, Benjamin, Campo, Meghan J., Gainor, Justin F.
Publicado no Oncologist (2016)

Thrombin-initiated platelet activation in vivo is vWF independent during thrombus formation in a laser injury model

Por Dubois, Christophe, Panicot-Dubois, Laurence, Gainor, Justin F., Furie, Barbara C., Furie, Bruce
Publicado em 2007

Survival in a case of diffuse alveolar hemorrhage due to Strongyloides stercoralis hyperinfection

Por Steinhaus, Daniel A., Gainor, Justin F., Vernovsky, Inna, Winsett, Julie, Beer, Dennis J.
Publicado em 2012

Alectinib Salvages CNS Relapses in ALK-Positive Lung Cancer Patients Previously Treated with Crizotinib and Ceritinib

Por Gainor, Justin F., Sherman, Carol A., Willoughby, Kathryn, Logan, Jennifer, Kennedy, Elizabeth, Brastianos, Priscilla K., Chi, Andrew S., Shaw, Alice T.
Publicado no J Thorac Oncol (2015)

Alectinib Dose Escalation Re-induces Central Nervous System Responses in ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients Relapsing on Standard Dose Alectinib

Por Gainor, Justin F., Chi, Andrew S., Logan, Jennifer, Hu, Ranliang, Oh, Kevin S., Brastianos, Priscilla K., Shih, Helen A., Shaw, Alice T.
Publicado no J Thorac Oncol (2015)

Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non–small cell lung cancer treated with radiotherapy for brain metastase...

Por Mak, Kimberley S., Gainor, Justin F., Niemierko, Andrzej, Oh, Kevin S., Willers, Henning, Choi, Noah C., Loeffler, Jay S., Sequist, Lecia V., Shaw, Alice T., Shih, Helen A.
Publicado no Neuro Oncol (2015)

Clinicopathologic Features of NSCLC Diagnosed During Pregnancy or the Peripartum Period in the Era of Molecular Genotyping

Por Dagogo-Jack, Ibiayi, Gainor, Justin F., Porter, Rebecca L., Schultz, Katherine R., Solomon, Benjamin J., Stevens, Sara, Azzoli, Christopher G., Sequist, Lecia V., Lennes, Inga T., Shaw, Alice T.
Publicado no J Thorac Oncol (2016)

Two novel ALK mutations mediate acquired resistance to the next generation ALK inhibitor alectinib

Por Katayama, Ryohei, Friboulet, Luc, Koike, Sumie, Lockerman, Elizabeth L., Khan, Tahsin M., Gainor, Justin F., Iafrate, A. John, Takeuchi, Kengo, Taiji, Makoto, Okuno, Yasushi, Fujita, Naoya, Engelman, Jeffrey A., Shaw, Alice T.
Publicado no Clin Cancer Res (2014)

Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib

Por Gainor, Justin F., Tan, Daniel S.W., De Pas, Tomasso, Solomon, Benjamin J., Ahmad, Aziah, Lazzari, Chiara, de Marinis, Filippo, Spitaleri, Gianluca, Schultz, Katherine, Friboulet, Luc, Yeap, Beow Y., Engleman, Jeffrey A., Shaw, Alice T.
Publicado no Clin Cancer Res (2015)

MET Exon 14 Skipping in Non-Small Cell Lung Cancer

Por Heist, Rebecca S., Shim, Hyo Sup, Gingipally, Shalini, Mino-Kenudson, Mari, Le, Long, Gainor, Justin F., Zheng, Zongli, Aryee, Martin, Xia, Junfeng, Jia, Peilin, Jin, Hailing, Zhao, Zhongming, Pao, William, Engelman, Jeffrey A., Iafrate, A. John
Publicado no Oncologist (2016)

A combinatorial strategy for treating KRAS mutant lung cancer

Por Manchado, Eusebio, Weissmueller, Susann, Morris, John P., Chen, Chi-Chao, Wullenkord, Ramona, Lujambio, Amaia, de Stanchina, Elisa, Poirier, John T., Gainor, Justin F., Corcoran, Ryan B., Engelman, Jeffrey A., Rudin, Charles M., Rosen, Neal, Lowe, Scott W.
Publicado no Nature (2016)

Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas

Por Yu, Helena A., Sima, Camelia S., Shen, Ronglai, Kass, Samantha, Gainor, Justin, Shaw, Alice, Hames, Megan, Iams, Wade, Aston, Jonathan, Lovly, Christine M., Horn, Leora, Lydon, Christine, Oxnard, Geoffrey R., Kris, Mark G., Ladanyi, Marc, Riely, Gregory J.
Publicado no J Thorac Oncol (2015)

ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer

Por Gainor, Justin F., Varghese, Anna M., Ou, Sai-Hong Ignatius, Kabraji, Sheheryar, Awad, Mark M., Katayama, Ryohei, Pawlak, Amanda, Mino-Kenudson, Mari, Yeap, Beow Y., Riely, Gregory J., Iafrate, A. John, Arcila, Maria E., Ladanyi, Marc, Engelman, Jeffrey A., Dias-Santagata, Dora, Shaw, Alice T.
Publicado em 2013

P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer

Por Katayama, Ryohei, Sakashita, Takuya, Yanagitani, Noriko, Ninomiya, Hironori, Horiike, Atsushi, Friboulet, Luc, Gainor, Justin F., Motoi, Noriko, Dobashi, Akito, Sakata, Seiji, Tambo, Yuichi, Kitazono, Satoru, Sato, Shigeo, Koike, Sumie, John Iafrate, A., Mino-Kenudson, Mari, Ishikawa, Yuichi, Shaw, Alice T., Engelman, Jeffrey A., Takeuchi, Kengo, Nishio, Makoto, Fujita, Naoya
Publicado no EBioMedicine (2015)

EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer (NSCLC): A Retrospective Analysis

Por Gainor, Justin F., Shaw, Alice T., Sequist, Lecia V., Fu, Xiujun, Azzoli, Christopher G., Piotrowska, Zofia, Huynh, Tiffany, Zhao, Ling, Fulton, Linnea, Schultz, Katherine R., Howe, Emily, Farago, Anna F., Sullivan, Ryan J., Stone, James R., Digumarthy, Subba, Moran, Teresa, Hata, Aaron N., Yagi, Yukako, Yeap, Beow Y., Engelman, Jeffrey A., Mino-Kenudson, Mari
Publicado no Clin Cancer Res (2016)